This is a trial to assess the best dose of aspirin to use in patients with stable coronary artery disease. Potential participants must receive care at UF Health, Orlando Health or Florida Hospital in Orlando. This is a three-year trial. Please contact 352.273.8933 or email firstname.lastname@example.org for more information.
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome
A heart attack happens when a blood vessel (coronary artery) supplying the heart muscle or one of its smaller branches is suddenly blocked, cutting off the supply of blood and oxygen to the heart muscle. This part of the heart muscle is at risk of dying unless the blockage is quickly removed. The most common cause of a heart attack is the build-up of excess cholesterol, which results in fatty deposits that cause the artery to become narrowed. Heart attacks can be life-threatening and patients can remain at high risk for further heart-related problems, even after recovery. This can be the result of either damage caused to the heart muscle or continued build-up of cholesterol. The purpose of this study is to find out how effective and safe CSL112 is at reducing the risk of dying from heart related events such as having another heart attack or having a stroke. Research studies have shown that a protein in the body called apolipoprotein A-I (ApoA-I) may help to remove excess cholesterol from the arteries. CSL112 is a mixture of ApoA-I from donated human blood and fats derived from soybeans. CSL112 resembles High Density Lipoprotein (HDL), which is sometimes better known as the ‘good cholesterol’. If participating in this trial, CSL112 will be administered to patients after a recent heart attack.
A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease.
The purpose of this study is to see how well a new liquid imaging tracer called Flurpiridaz (F-18), which contains a very small dose of radioactivity, can detect coronary artery disease (CAD) during a PET (positron emission tomography) scan. We will compare images of your heart taken from a procedure called a SPECT (single photon emission computed tomography) scan. We will then compare the SPECT scan images to a Flurpiridaz (F-18) injected PET scan procedure of your heart. The PET scan images using Flurpiridaz (F-18) will also be compared to the results of your cardiac catheterization. These comparisons will help us test how accurate PET scan images are when used with Flurpiridaz (F-18). We will also collect information to evaluate the safety of Flurpiridaz (F-18) during this study.
An integrated human organ-on-chip ultrasensitive miRNA detection platform for novel biomarker discovery
This study is being done because researchers are trying to recreate a miniature version of the heart on an electronic chip using stem cells. This is called a “heart-on-a-chip,” and if successful, it may help researchers discover new molecules that can help detect heart disease. Blood from both healthy and sick participants is needed to verify that the molecules produced by the heart-on-a-chip are similar to those that are normally or abnormally produced in the human body. For this study, the abnormal condition to be studied is heart attack. Blood from both healthy persons and persons that have a heart attack will be collected in order to confirm the heart-on-a-chip is a useful way of studying new diagnostic molecules for health or disease.
Women’s IschemiA TReatment Reduces Events In Non-ObstRuctive CAD
WARRIOR is a four-year, multicenter clinical trial to determine whether aggressive treatment of nonobstructive coronary artery disease (CAD) with medication and lifestyle modification will reduce the likelihood of major adverse events such as stroke, heart attack, heart failure, hospitalization, and death.